BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia
Clinical Lymphoma Myeloma and Leukemia · 2026-07 · 26 (7) · 447-455
DOI: 10.1016/j.clml.2026.04.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-07. Verfasst von Eman O Rasekh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Imatinib Mesylate, Protein Kinase Inhibitors. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment. Early assessment of TKI response is crucial, and while deep molecular responses enable treatment discontinuation in selected patients, strict eligibility criteria are needed to prevent relapse. This study aimed to evaluate factors affecting early response to first-line imatinib in CML to help define criteria for safe treatment discontinuation and achieving treatment-free remission (TFR). PATIENTS AND METHODS This retrospective cohort study included all adult patients diagnosed with CML who received first-line imatinib therapy between February 2016 and February 2020. RESULTS A total of 144 adult patients with CML were included. The median age at diagnosis was 40 years (range: 21-76 years). Early molecular response (EMR), defined as BCR-ABL1 transcript level ≤10% international scale, was achieved in 72 of 116 evaluable patients (62%), and these patients demonstrated significantly superior event-free survival (p = .001), overall survival (p = .003), and failure-free survival (FFS, p < .001) compared with those without EMR. High-risk scores in SOKAL, ELTS, Hasford, and EUTOS systems were associated with EMR failure. Complete hematologic remission at 3 months (p = .001) and achieving BCR-ABL1 log reductions at 3, 6, and 12 months predicted improved FFS. The b3a2 BCR-ABL1 transcript and achieving BCR-ABL1 levels ≤10% at 3 months were both significantly linked to eligibility for treatment discontinuation (p = .04 and p < .0001, respectively). CONCLUSION EMR should be considered a strong surrogate marker for identifying treatment failure. Imatinib-treated patients achieving EMR and carrying the b3a2 BCR-ABL1 transcript may be suitable for TFR if closely monitored under strict protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Electronic address: Sally.elfishawi@nci.cu.edu.eg.
Zitieren
APA
Rasekh, E. O., Sherif, M. M., Ibrahim, N., Ibraheem, D., Ghareeb, M., & Elfishawi, S. (2026). BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia, 26(7), 447-455. https://doi.org/10.1016/j.clml.2026.04.007
Vancouver
Rasekh EO, Sherif MM, Ibrahim N, Ibraheem D, Ghareeb M, Elfishawi S. BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2026;26(7):447-455. doi:10.1016/j.clml.2026.04.007
BibTeX
@article{Rasekh2026,
author = {Rasekh, Eman O and Sherif, Menna M and Ibrahim, Nagwa and Ibraheem, Dalia and Ghareeb, Mohamed and Elfishawi, Sally},
title = {BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {7},
pages = {447--455},
doi = {10.1016/j.clml.2026.04.007}
}
EUVIMED